AstraZeneca: TAGRISSO Plus Chemotherapy Granted Priority Review in the US for Patients With EGFR-Mutated Advanced Lung Cancer
October 17, 2023
October 17, 2023
WILMINGTON, Delaware, Oct. 17 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The Food and Drug Administr . . .
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The Food and Drug Administr . . .